CDM1101

CDM1101 is a novel human peptide therapeutic candidate in preclinical development. It has been shown to stimulate the neogenesis or differentiation of human islets within pancreatic tissue in vitro. Animal proof-of-concept studies are being conducted at Calvert Laboratories in Scranton, PA. Early results indicate that the animals treated with HIP have a reduced requirement for exogenous insulin compared to those treated with placebo. The effects of HIP on c-peptide levels and islet number are also being evaluated in mouse studies.

Key features and competitive advantages include:

• Short course of treatment of 1-3 months instead of lifelong treatment with insulin
• Restores physiology instead of just replacing only one of the missing hormones in diabetes
• Requires no transplant procedures
• Requires no use of stem cells
• Utilizes a normal physiologic process of islet regeneration